RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Ultragenyx Pharmaceutical Inc. (RARE) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Revisions (F). The rating has held at C- for 4 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | B (3.2) | B (3.3) | C+ (2.6) | D (1.4) | F (0.0) | C- (2.1) |
| 2026-11-07 | B (3.2) | B (3.3) | C+ (2.5) | D (1.3) | F (0.0) | C- (2.1) |
| 2026-10-31 | C (2.2) | B+ (3.5) | C+ (2.6) | D (1.3) | F (0.0) | C- (1.9) |
| 2026-10-24 | C (2.3) | B (3.5) | C+ (2.5) | D- (1.1) | F (0.0) | C- (1.9) |
| 2026-10-17 | C (2.4) | B (3.5) | C+ (2.5) | D- (1.0) | F (0.0) | C- (1.9) |